Biotechnology Assets S.A. - Asset Resilience Ratio
Biotechnology Assets S.A. (BST) has an Asset Resilience Ratio of 0.34% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BST FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how Biotechnology Assets S.A.'s Asset Resilience Ratio has changed over time. See BST net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Biotechnology Assets S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Biotechnology Assets S.A. market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €46.18K | 0.34% |
| Total Liquid Assets | €46.18K | 0.34% |
Asset Resilience Insights
- Limited Liquidity: Biotechnology Assets S.A. maintains only 0.34% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Biotechnology Assets S.A. Industry Peers by Asset Resilience Ratio
Compare Biotechnology Assets S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hugel Inc
KQ:145020 |
Biotechnology | 29.57% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Absci Corp
NASDAQ:ABSI |
Biotechnology | 59.86% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for Biotechnology Assets S.A. (2010–2024)
The table below shows the annual Asset Resilience Ratio data for Biotechnology Assets S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.32% | €46.62K ≈ $54.50K |
€14.78 Million ≈ $17.28 Million |
+0.04pp |
| 2023-12-31 | 0.27% | €44.90K ≈ $52.50K |
€16.61 Million ≈ $19.42 Million |
-0.20pp |
| 2022-12-31 | 0.47% | €86.70K ≈ $101.37K |
€18.47 Million ≈ $21.60 Million |
+0.34pp |
| 2021-12-31 | 0.12% | €24.79K ≈ $28.98K |
€19.88 Million ≈ $23.24 Million |
0.00pp |
| 2020-12-31 | 0.13% | €25.51K ≈ $29.82K |
€20.21 Million ≈ $23.63 Million |
-1.11pp |
| 2019-12-31 | 1.23% | €1.14 Million ≈ $1.33 Million |
€92.67 Million ≈ $108.34 Million |
-0.22pp |
| 2018-12-31 | 1.45% | €1.15 Million ≈ $1.34 Million |
€79.24 Million ≈ $92.64 Million |
-3.57pp |
| 2017-12-31 | 5.02% | €882.53K ≈ $1.03 Million |
€17.58 Million ≈ $20.56 Million |
-0.87pp |
| 2016-12-31 | 5.89% | €940.06K ≈ $1.10 Million |
€15.97 Million ≈ $18.67 Million |
-0.13pp |
| 2015-12-31 | 6.02% | €890.19K ≈ $1.04 Million |
€14.80 Million ≈ $17.30 Million |
-0.07pp |
| 2014-12-31 | 6.08% | €893.01K ≈ $1.04 Million |
€14.68 Million ≈ $17.17 Million |
+4.22pp |
| 2013-12-31 | 1.86% | €172.12K ≈ $201.23K |
€9.25 Million ≈ $10.81 Million |
-3.87pp |
| 2012-12-31 | 5.73% | €436.07K ≈ $509.81K |
€7.61 Million ≈ $8.90 Million |
+4.20pp |
| 2011-12-31 | 1.53% | €111.46K ≈ $130.31K |
€7.29 Million ≈ $8.53 Million |
-12.36pp |
| 2010-12-31 | 13.89% | €698.48K ≈ $816.60K |
€5.03 Million ≈ $5.88 Million |
-- |
About Biotechnology Assets S.A.
Biotechnology Assets, S.A. develops and markets biotechnological assets for applications in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industries in Spain and internationally. It offers SPLITTERA, a protein engineering tool that allows the conjugation of proteins through the formation of new peptide bonds; universal switchable split-chimeric antigen receptor (CAR); VA… Read more